Pancreatic cancer care at Mount Sinai has reached a new pinnacle with the creation of the Center of Excellence for Pancreatic Cancer (COE) and Center of Excellence for Pancreatic Cancer Multidisciplinary Team. With a focus on holistic care and novel therapeutics for optimal outcomes, the Center and Pancreas Team provide comprehensive and compassionate care in close collaboration with referring physicians.
Mount Sinai has one of the most experienced pancreatic disorders treatment programs in the United States. We are recognized by the National Pancreas Foundation for our multidisciplinary “whole patient” approach in treating pancreatitis and pancreatic cancer. We received grant funding from the Canopy Cancer Collective—a network that connects expert clinicians and researchers to foster optimal cancer care and improved outcomes—to enhance and maximize our multidisciplinary approach to the treatment of pancreatic cancer. And, we belong to the Pancreatic Cancer Early Detection Consortium (PRECEDE), an international group of 35 centers that are working together to transform risk assessment, and early detection and prevention of pancreatic cancer.
Our multidisciplinary team, comprised of national leaders in gastroenterology, medical oncology, radiation oncology, pathology, and radiology, provides the highest-quality diagnostic evaluation, treatment, and care, as well as access to innovative therapies through clinical trials at four Mount Sinai locations. We utilize multiple diagnostic tools, including CT, MRI, endoscopic retrograde cholangiopancreatography, and endoscopic ultrasound, and offer genetic testing. The team collaborates via our Pancreas Tumor Board to customize a personalized treatment plan for each patient.
Center of Excellence for Pancreatic Cancer Multidisciplinary Team Mount Sinai West 425 West 59th Street New York, NY 10019 For appointments, call 1-877-516-PAN1.
Center of Excellence for Pancreatic Cancer Treatment Locations:
• The Blavatnik Family – Chelsea Medical Center at Mount Sinai
In addition to performing common surgical procedures for localized cancer—distal pancreatectomy, pancreaticoduodenectomy (Whipple procedure), and total pancreatectomy—our surgeons are skilled in the latest robotic techniques, including irreversible electroporation.
For our patients receiving chemotherapy and radiation therapy for pancreatic cancer, we are pioneering new techniques such as precise tumor targeting using real-time imaging during radiotherapy delivery and respiratory gating to minimize the impact of breathing motion during treatment. We are also identifying multi-drug regimens that may extend survival.
A special component of the Center of Excellence for Pancreatic Cancer is our Center of Excellence for Pancreatic Cancer Multidisciplinary Team at Mount Sinai West. This is a well-coordinated one-stop shop that provides comprehensive diagnostics, evaluation, and a personalized treatment plan, all in one day and at one location.
“At the end of their visits, patients walk out with an easy-to-understand-and-follow treatment plan, put together by some of the best minds for treating and researching pancreatic cancer,” said Karyn A. Goodman, Professor and Vice Chair for Research and Quality in the Department of Radiation Oncology at the Icahn School of Medicine at Mount Sinai, Associate Director for Clinical Research at The Tisch Cancer Institute, and Co-director of the Center of Excellence for Pancreatic Cancer. “It can take several weeks for a patient to get a treatment plan for pancreatic cancer. We do it in one day.”
The integration of specialists from multiple medical and surgical disciplines enables us to quickly and efficiently design a personalized care plan. We communicate with the patient’s referring physician about the plan and encourage ongoing dialogue.
Patients seen at the Center of Excellence for Pancreatic Cancer and the Pancreas Multidisciplinary Treatment Team have access to the full array of Mount Sinai’s medical expertise and extensive supportive care services. In partnership with referring physicians, we make the overwhelming diagnosis of pancreatic cancer manageable and offer the prospect of the best possible outcome for each patient.